NEW YORK – Quotient Limited announced on Tuesday that it has partnered with Infynity Biomarkers to develop infectious disease tests for Quotient’s MosaiQ platform.
Under the collaboration agreement, infectious disease biomarker firm Infynity will help with the research and design of tests to expand Quotient’s MosaiQ Serology Disease Screening menu and will work to reduce the time and cost for assay development and commercialization. The automated MosaiQ platform uses multiplex microarray technology to provide testing across different modalities.
Lyon, France-based Infynity is developing antibodies and antigens for multiplex infectious disease blood screening, confirmatory testing, determining vaccine efficacy, and monitoring testing, all of which will be evaluated as part of the collaboration, Quotient said in a statement.
Financial and other terms of the deal were not disclosed.
Partnerships like the one with Infynity “will enable us to access the infectious disease screening and clinical diagnostic markets with a highly differentiated and competitive offering,” Quotient CEO Manuel Méndez said in a statement.
Last month, Eysins, Switzerland-based Quotient announced a partnership with Theradiag to develop autoimmune diagnostics on the MosaiQ, with Theradiag providing autoimmune reagents and multi-constituent quality controls.